P2RX3 and chronic kidney disease: These include a highly selective P2X7 antagonist being developed for the treatment of chronic kidney disease [117] and P2X3 antagonists such as Gefapixant, which has been FDA-approved for the treatment of refractory chronic cough, and Filapixant, which is undergoing clinical trials to assess its safety, tolerability, and pharmacokinetics [118].